Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.50 |
| ▸ | ATP4B | P51164 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996228 | 0.85 | ATP4A (0.53) | ATP4AATP4BCYP19A1QPCTMEN1 | |
| SCHEMBL22397927 | 0.81 | MEN1 (0.55) | ATP4AATP4BCYP19A1QPCTMEN1 | |
| SCHEMBL765017 | 0.81 | QPCT (0.56) | ATP4AATP4BCYP19A1QPCTMEN1 | |
| SCHEMBL13201562 | 0.81 | ATP4A (0.53) | ATP4AATP4BCYP19A1ERBB2MINK1 | |
| SCHEMBL14189706 | 0.79 | ATP4A (0.52) | ATP4AATP4BCYP19A1MEN1KMT2A | |
| SCHEMBL5564341 | 0.79 | ATP4A (0.52) | ATP4AATP4BCYP19A1QPCTMEN1 | |
| SCHEMBL5046643 | 0.79 | ATP4A (0.52) | ATP4AATP4BCYP19A1QPCTMEN1 | |
| SCHEMBL18837867 | 0.79 | ATP4A (0.52) | ATP4AATP4BCYP19A1QPCTMEN1 | |
| SCHEMBL13617693 | 0.79 | CYP3A4 (0.43) | CYP19A1QPCTMEN1KMT2AATM | |
| SCHEMBL16417747 | 0.78 | MEN1 (0.59) | ATP4AATP4BCYP19A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | ATP4A 1393/4885ATP4B 1730/4885CYP19A1 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.